ASCO GI 2021 | Highlights from ASCO GI 2021

Brian H. Ramnaraign, MD, University of Florida College of Medicine, Gainesville, FL, discusses key data presented at this years American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, including the results of the Phase II FIGHT study (NCT03694522) evaluating bemarituzumab in combination with modified FOLFOX6 in patients with gastric cancer. Dr Ramnaraign also outlines an abstract investigating circulating tumor DNA analysis for assessment of recurrence risk, benefit of adjuvant therapy, and early relapse detection after treatment in colorectal cancer patients. Finally, a Phase II/III randomized double-blind study of octreotide acetate with axitinib versus octreotide acetate with placebo in patients with advanced G1-G2 NETs of non-pancreatic origin (AXINET trial-GETNE-1107) is discussed by Dr Ramnaraign, as well as the results of the Alliance A021501 trial. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).